Condition 1: Obesity. Condition 2: Metabolic syndrome. Obesity Other metabolic disorders
Conditions
Interventions
Intervention 1: Intervention group was provided 2 servings/day of FY (2×250 ml/day) plus weight-loss diet for 10 weeks. One serving of FY contained 5 g whey protein, 3 g inulin as perbiotic, 500 mg ca
Treatment - Other
Intervention group was provided 2 servings/day of FY (2×250 ml/day) plus weight-loss diet for 10 weeks. One serving of FY contained 5 g whey protein, 3 g inulin as perbiotic, 500 mg calcium, 500 IU vi
Control group was provided 2 servings/day of CY (2×250 ml/day) containing Lactobacillus bulgaricus and Streptococcus thermophile plus weight-loss diet for 10 weeks.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria: aged between 20 and 60 years and a BMI of 25.0–35 kg/m2. The metabolic syndrome was diagnosed as having three of the following five features: waist circumference (=102 cm in men and =88 cm in women); try glycerol levels (=150 mg/dl); HDL-C levels (<40 mg/dl in men and <50 mg/dl in women); blood pressure (=130/ 85mmHg or on treatment for hypertension); glucose levels (=100 mg/dl. The ability to understand the study protocol and provide written informed consent. The exclusion criteria were as follows: an inability or unwillingness to participate; antibiotic treatment; more than 10% weight change over the preceding 6 months; recent (four weeks) changes in exercise intensity or frequency; nonconsumption of low-fat yogurts habitually; consumption of probiotic products habitually; intake of medications that could affect body weight, calcium or vitamin D metabolism; taking drugs for blood glucose or lipid control; taking multivitamin-mineral supplements, omega-3 and oral contraceptive peel; Allergy to probiotic or dairy products; smoking or alcohol consumption; serious medical illnesses including cardiovascular, gastrointestinal, cancer, neurologic, renal, hepatic, endocrine, rheumatoid, thyroid and eating disorders. We also excluded the pregnant or lactating women. We also made sure that the subjects had not participated in any other weight management studies within the last 6 months of screening. Other exclusion criteria during the study included: non-compliance to the study protocol; the occurrence of serious adverse events and any changes in intensity or frequency of exercise.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Homeostasis model assessment of insulin resistance (HOMA-IR). Timepoint: Pre and 10 weeks after intervention. Method of measurement: Equation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropometric indices (weight, waist circumference, BMI). Timepoint: Pre and post intervention. Method of measurement: Pre and post intervention.;Body composition measurements (Fat mass and fat free mass). Timepoint: At the beginning and at the end of the study. Method of measurement: BIA.;Fasting blood glucose. Timepoint: At the beginning and at the end of the study. Method of measurement: Biochemical.;Serum insulin. Timepoint: At the beginning and at the end of the study. Method of measurement: ELISA.;Lipid profile (triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL) and high density lipoprotein (HDL) ). Timepoint: At the beginning and at the end of the study. Method of measurement: Enzymatic methods.;Blood pressure. Timepoint: At the beginning and at the end of the study. Method of measurement: Digital Barometer.;25 (OH)vit D. Timepoint: At the beginning and at the end of the study. Method of measurement: ELISA.;Serum MDA. Timepoint: At the beginning and at the end of the study. Method of measurement: TBARS method.;Hs-CRP. Timepoint: At the beginning and at the end of the study. Method of measurement: ELISA.;Serum adiponectin. Timepoint: At the beginning and at the end of the study. Method of measurement: ELISA.;Endothelin-1. Timepoint: At the beginning and at the end of the study. Method of measurement: ELISA.;Appetite status. Timepoint: At the beginning, at 5 weeks and at the end of the study. Method of measurement: by visual analog scales (VAS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Mohammadi Sartang
Shiraz University of Medical sciences
Outcome results
None listed